These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28438688)

  • 1. Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    J Hepatol; 2017 Nov; 67(5):1106-1108. PubMed ID: 28438688
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
    Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
    J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of hepatitis B virus from an isolated anti-HBc positive patient after eradication of hepatitis C virus with direct-acting antiviral agents.
    Suda T; Shimakami T; Shirasaki T; Yamashita T; Mizukoshi E; Honda M; Kaneko S
    J Hepatol; 2017 Nov; 67(5):1108-1111. PubMed ID: 28739112
    [No Abstract]   [Full Text] [Related]  

  • 4. Direct-acting antivirals and hepatitis B virus (HBV) reactivation in co-infected HBV/HCV kidney-transplant recipients.
    Pol S; Marion O; Vallet-Pichard A; Meritet JF; Sauné K; Alric L; Kamar N
    Transpl Infect Dis; 2018 Jun; 20(3):e12864. PubMed ID: 29512231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
    Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.
    Mouna L; Rossignol E; Tateo M; Coilly A; Duclos-Vallée JC; Duvoux C; Durand F; Tran A; Radenne S; Canva-Delcambre V; Houssel-Debry P; Dumortier J; Conti F; de Ledinghen V; Leroy V; Kamar N; Di Martino V; Moreno C; Botta Fridlund D; d'Alteroche L; Lebray P; Perre P; Besch C; Silvain C; Habersetzer F; Debette-Gratien M; Abergel A; Diallo A; Samuel D; Roque-Afonso AM; Pageaux GP;
    J Hepatol; 2019 Jun; 70(6):1297-1300. PubMed ID: 30967293
    [No Abstract]   [Full Text] [Related]  

  • 8. Examining Hepatitis, A and B Vaccination, and HBV Reactivation Monitoring During Direct-Acting Antiviral Therapy for Hepatitis C.
    Davison J; O'Shea A; Waterbury N; Villalvazo Y
    J Community Health; 2018 Dec; 43(6):1124-1127. PubMed ID: 29846860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV).
    Blackard JT; Sherman KE
    Rev Med Virol; 2018 Jul; 28(4):e1984. PubMed ID: 29761585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen.
    Londoño MC; Lens S; Mariño Z; Bonacci M; Ariza X; Broquetas T; Pla A; Bartres C; Adriani MV; Rodríguez-Tajes S; Costa J; Carrión JA; Pérez-Del-Pulgar S; Forns X
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1156-1161. PubMed ID: 28206681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation.
    Fang J; Li W; Tan M; Chen W; Zhang C; Wang W; Xu Q; Guo X
    Int Urol Nephrol; 2018 Sep; 50(9):1653-1660. PubMed ID: 29644524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Sulkowski MS; Chuang WL; Kao JH; Yang JC; Gao B; Brainard DM; Han KH; Gane E
    Clin Infect Dis; 2016 Nov; 63(9):1202-1204. PubMed ID: 27486112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
    Reddy KR; Beavers KL; Hammond SP; Lim JK; Falck-Ytter YT;
    Gastroenterology; 2015 Jan; 148(1):215-9; quiz e16-7. PubMed ID: 25447850
    [No Abstract]   [Full Text] [Related]  

  • 15. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
    Liu CJ
    J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection.
    Odolini S; Lanza P; Angiola A; Zaltron S; Urbinati L; Vavassori A; Nasta P; Festa E; Gargiulo F; Rodella A; Caruso A; Casari S; Castelli F; Viganò M
    New Microbiol; 2017 Jul; 40(3):218-220. PubMed ID: 28513813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers.
    Renou C; Cadranel JF; Pariente A; Pénaranda G; Bourlière M; Halfon P; Igual JP; Harafa A; Muller P; Bertrand JJ; Laugier R
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1235-7. PubMed ID: 18989147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.
    Yeh ML; Huang CF; Hsieh MH; Ko YM; Chen KY; Liu TW; Lin YH; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CI; Huang JF; Kuo PL; Dai CY; Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2017 Oct; 32(10):1754-1762. PubMed ID: 28230928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.